Stocksigma LogoStocksigma Logo

Goldline Pharmaceutical Reports H1 FY27 Results with 44.5% Net Profit Growth

Goldline Pharmaceutical reported standalone revenue from operations of ₹1,492.50 lakh for the half-year ended 30th Sep'26, up 7.4% YoY from ₹1,389.21 lakh

Goldline Pharmaceutical Reports H1 FY27 Results with 44.5% Net Profit Growth

Goldline Pharmaceutical Ltd · Financial Result · 15 Nov 2026, 1:11 am

Goldline Pharmaceutical Reports H1 FY27 Results with 44.5% Net Profit Growth Goldline Pharmaceutical reported standalone revenue from operations of ₹1,492.50 lakh for the half-year ended 30th Sep'26, up 7.4% YoY from ₹1,389.21 lakh in H1 FY26. Net profit rose 44.5% YoY to ₹205.15 lakh compared to ₹141.96 lakh, supported by higher operating profit and lower finance costs of ₹27.92 lakh versus ₹66.63 lakh. Basic and diluted EPS improved to ₹2.31 from ₹1.96. Total shareholder funds expanded significantly to ₹2,593.55 lakh from ₹1,424.96 lakh as of 31st Mar'26, following equity and share premium additions.

Original exchange filing (PDF)

More announcements from Goldline Pharmaceutical Ltd

All Goldline Pharmaceutical Ltd announcements